Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy-Reference-Cited by-同舟云学术

Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy

Published:2023-10-20 Issue:1 Volume:103 Page:259-268
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Winkelmann Michael,Blumenberg Viktoria,Rejeski Kai,Quell Christina,Bücklein Veit L.,Ingenerf Maria,Unterrainer Marcus,Schmidt Christian,Dekorsy Franziska J.,Bartenstein Peter,Ricke Jens,von Bergwelt-Baildon Michael,Subklewe Marion,Kunz Wolfgang G.

Funder

the Bavarian Cancer Research Center

Else Kröner-Fresenius-Stiftung

Deutschen Konsortium für Translationale Krebsforschung

Medical Faculty LMU, "FöFoLe"

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05507-9.pdf

Reference34 articles.

1. June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64–73. https://doi.org/10.1056/NEJMra1706169

2. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45–56. https://doi.org/10.1056/NEJMoa1804980

3. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377:2545–2554. https://doi.org/10.1056/NEJMoa1708566

4. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531–2544. https://doi.org/10.1056/NEJMoa1707447

5. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331–1342. https://doi.org/10.1056/NEJMoa1914347

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDG-PET/CT Imaging in Chimeric Antigen Receptor–Engineered T-Cell Treatment in Patients with B-Cell Lymphoma;PET Clinics;2024-10

2. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy;Seminars in Immunopathology;2024-07-16

3. The Role of [18F]FDG PET/CT in Predicting Toxicity in Patients with NHL Treated with CAR-T: A Systematic Review;Tomography;2024-06-03